Shareholders to Vote on Significant Share Issuance Authority and Capital Increase Amidst Clinical Setbacks

summarizeSummary

uniQure N.V. filed its definitive proxy statement, seeking shareholder approval for proposals including the authority to issue up to 19.7% of outstanding shares, increasing authorized capital by 20 million shares, and reauthorizing a 10% share repurchase program.

check_boxKey Events

• Board Seeks Authority for Significant Share Issuance

  Shareholders will vote on granting the Board authority to issue up to 12.4 million ordinary shares, representing approximately 19.7% of the company's currently issued and outstanding share capital. This provides substantial flexibility for future capital raises but also significant potential for dilution.

• Increase in Authorized Share Capital Proposed

  The company proposes to amend its Articles of Association to increase the authorized share capital from 80 million to 100 million shares. This expands the long-term capacity for future share issuances, which could be used for financing or strategic transactions.

• Reauthorization of Share Repurchase Program

  The Board is seeking reauthorization to repurchase up to 10% of the company's issued share capital. This provides the company with the flexibility to buy back shares, potentially offsetting some dilution or returning value to shareholders if the stock is deemed undervalued.

• Increase in Equity Incentive Plan Shares

  Shareholders will vote on increasing the number of shares available under the 2014 Share Incentive Plan by an additional 350,000 shares for employee equity awards. This represents a modest potential dilution for compensation purposes.

auto_awesomeAnalysis

uniQure N.V. is seeking shareholder approval for several proposals that could significantly impact its capital structure and future financing capabilities. The most material proposals include authorizing the Board to issue up to 12.4 million ordinary shares, representing approximately 19.7% of current outstanding shares, and increasing the total authorized share capital from 80 million to 100 million shares. These measures provide substantial flexibility for future capital raises, which is critical given the recent FDA rejection for its lead candidate AMT-130 and clinical trial pauses for other programs. While necessary for funding ongoing operations and development, these proposals carry a significant potential for dilution for existing shareholders. The reauthorization of a share repurchase program (up to 10% of issued capital) offers a potential counter-balance, but its execution is discretionary. This definitive proxy statement follows a preliminary filing on April 16, 2026, providing full details of the proposals.